Hold Laurus Labs; target of Rs 368: Sharekhan
Sharekhan recommended Hold rating on Laurus Labs with a target price of Rs 368 in its research report dated January 31, 2023.02-02-2023
02-02-2023
Buy Laurus Labs; target of Rs 440: Motilal Oswal
Motilal Oswal is bullish on Laurus Labs recommended buy rating on the stock with a target price of Rs 440 in its research report dated January 30, 2023.01-02-2023
Laurus Labs slips 5%, hits over 2-year low post December quarter results
Laurus Labs delivered operationally in-line performance, led by healthy traction in CDMO-Synthesis/Non-ARV API segment31-01-2023
Laurus Labs shares tumble as Jefferies cuts target price
Choice Equity Broking, too, expects muted growth for the drugmaker because of a decline in margins due to a change in product mix and operating de-leverage31-01-2023
Laurus Labs Results Earnings Call for Q3FY23
Conference Call with Laurus Labs Management and Analysts on Q3FY23 Performance and Outlook. Listen to the full earnings transcript.31-01-2023
Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulation 30 & 46 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and with reference to our Results conference call intimation dated January 21, 2023, please be informed that the Results conference call for Q3 FY23 was hosted on January 30, 2023 and the web link for the audio recording of the conference call is as follows: Audio Recording Please take the information on record.30-01-2023
Laurus Labs' Q3 net up 32 pc at 203 cr
Total revenue increased 50 per cent to 1,545 crore30-01-2023
Q3FY23 Quarterly Result Announced for Laurus Labs Ltd.
Pharmaceuticals firm Laurus Labs announced Q3FY23 results: Q3FY23: Revenue at Rs 1,545 crore, increased 50% (YoY) EBITDA at Rs 404 crore, increased by 39% (YoY) EBITDA margins at 26.1%. PAT at Rs 203 crore, increased by 32% (YoY) PAT margins at 13%. EPS (Diluted) for the period at Rs 3.7 per share (not annualised) 9MFY23: Revenue at Rs 4,660 crore, increased 33% (YoY) EBITDA at Rs 1,307 crore, increased by 26% (YoY) EBITDA margins at 28%. PAT at Rs 687 crore, increased by 15% (YoY) PAT margins at 15%. EPS (Diluted) (face value of Rs 2/-) for the period at Rs 12.7 per share (not annualised) Commenting on the highlights, Founder and Chief Executive Officer Dr. Satyanarayana Chava stated “Our Q3FY23 and 9MFY23 results reflects sustained business momentum across our key growth drivers, which is visible in our commercial execution within CDMO, and Non-ARVs generic portfolio. The growth is also supported by anticipated recovery in ARV FDF segment, which is likely to continue despite pricing challenges. Our recent success with the Global funds HIV procurement as ‘Panel Supplier’ demonstrates our committed to the cause of HIV. We also made additional advancements in our R&D; initiatives and brought new capacities on line. We continue to execute on our strategy, prioritize investment into durable growth pillars, scaling up capacities and deliver profitable growth in long run." Commenting on the results, V V Ravi Kumar, Executive Director & Chief Financial Officer said; “We are pleased to report another strong quarter with operational results on expected lines. In Q3FY23, Laurus Lab clocked 50% revenue growth to Rs 1,545 crore, driven by continued strong demand in our CDMO-Synthesis business and steady ramp up in API business. During 9MFY23, our overall operational performance was healthy; Revenues are up 33% to Rs 4,660 crore and EBITDA grew by 26% with EBITDA margins of ~ 28%. Our ROCE on annualised basis stood healthy ~ 26% with comfortable Balance sheet position. We believe our Capital allocation framework including commitment towards diversification and strengthening non-ARV portfolio, building niche capabilities, and improving operational efficiency will continue to be in force in creating long term value”. Result PDF30-01-2023
Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation30-01-2023
Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
press release30-01-2023